2023
An overview of novel therapies in advanced clinical testing for acute myeloid leukemia
Venugopal S, Xie Z, Zeidan A. An overview of novel therapies in advanced clinical testing for acute myeloid leukemia. Expert Review Of Hematology 2023, 16: 109-119. PMID: 36718500, DOI: 10.1080/17474086.2023.2174521.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAML therapyMolecular pathogenesisApproval of midostaurinPathophysiology of AMLMeasurable residual diseaseAdvanced clinical testingClinical trial developmentAcute myeloid leukemiaCell surface antigensDevelopment of agentsDisease relapseImmune environmentAML treatmentResidual diseaseTherapeutic armamentariumMyeloid leukemiaNovel therapiesSurface antigenClinical testingTrial developmentTherapyAMLEscape mechanismsGene mutationsRelapse
2013
The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy)
Zeidan A, Forde P, Symons H, Chen A, Smith B, Fuchs E, Luznik L, Jones R, Bolaños-Meade J. The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy). Blood 2013, 122: 4629. DOI: 10.1182/blood.v122.21.4629.4629.Peer-Reviewed Original ResearchDonor lymphocyte infusionPosttransplantation cyclophosphamideComplete responseGVHD prophylaxisMRD relapseLymphocyte infusionHematologic relapseCR rateDoses of DLIHLA-haploidentical bone marrow transplantationReasonable starting doseBone marrow transplantationDisease-specific criteriaOff-label useDuration of survivalAML ptsChronic GVHDAllogeneic BMTSevere graftStarting doseUnacceptable toxicityDonor chimerismMedian ageDisease relapseMarrow transplantation